Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105146 | 0.84 | IKBKB (0.48) | RAB9ALMNAALDH1A1KDM4EHPGD | |
| SCHEMBL1244840 | 0.79 | LRRK2 (0.48) | LMNAMEN1GAAKMT2A | |
| SCHEMBL105959 | 0.78 | RAB9A (0.42) | RAB9ALMNACA1CA2ALDH1A1 | |
| SCHEMBL13170545 | 0.73 | RAB9A (0.48) | RAB9ALMNACA1CA2ALDH1A1 | |
| SCHEMBL27778836 | 0.71 | MEN1 (0.49) | RAB9ALMNAALDH1A1KDM4EHPGD | |
| SCHEMBL13745059 | 0.71 | RAB9A (0.69) | RAB9ALMNACA1CA2ALDH1A1 | |
| SCHEMBL13316477 | 0.69 | GAA (0.50) | ALDH1A1KDM4EMEN1GAAKMT2A | |
| SCHEMBL27971823 | 0.69 | RAB9A (0.45) | RAB9ACA1CA2ALDH1A1CA4 | |
| SCHEMBL15048567 | 0.68 | LMNA (0.41) | RAB9ALMNACA1CA2ALDH1A1 | |
| SCHEMBL16485987 | 0.67 | MEN1 (0.55) | LMNACA1CA2ALDH1A1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2011013729-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | オンコセラピー・サイエンス株式会社 (JP) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | RAB9A 3030/4885LMNA 3669/4885CA1 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.